Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes

Published:2018-08-13 Issue:12 Volume:20 Page:2821-2829
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Rosenstock Julio¹^ORCID,Handelsman Yehuda²,Vidal Josep³⁴,Ampudia Blasco F. Javier⁵,Giorgino Francesco⁶^ORCID,Liu Minzhi⁷,Perfetti Riccardo⁸,Meier Juris J.⁹^ORCID

Affiliation:

1. Dallas Diabetes Research Center at Medical City; Dallas Texas

2. Metabolic Institute of America; Tarzana California

3. Hospital Clinic of Barcelona; Barcelona Spain

4. Centro Investigación Biomédica en Red en Diabetes y Enfermeades Metabólicas (CIBERDEM); Madrid Spain

5. Clinic University Hospital of Valencia; Valencia Spain

6. University of Bari Aldo Moro; Bari Italy

7. BDM Consulting, Inc.; Somerset New Jersey

8. Sanofi; Bridgewater New Jersey

9. St Josef Hospital, Ruhr-University Bochum; Bochum Germany

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13462/fullpdf

Reference27 articles.

1. Standards of medical care in diabetes-2017;American Diabetes Association;Diabetes Care,2017

2. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus;Meier;Nat Rev Endocrinol,2012

3. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus;Owens;Diabetes Metab,2013

4. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial;Meier;Diabetes Care,2015

5. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study;Drucker;Lancet,2008

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study;Diabetes Research and Clinical Practice;2024-03

2. Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study;Diabetes Therapy;2023-06-08

3. The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2022-02-13

4. Strategies of Polypharmacology;Polypharmacology;2022

5. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus;Expert Opinion on Drug Safety;2021-10-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3